about
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future PerspectivesATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersEpigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Epithelial ovarian cancer: An overview.Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.Olaparib: a promising PARP inhibitor in ovarian cancer therapy.An overview of early investigational therapies for chemoresistant ovarian cancer.Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.Cediranib in ovarian cancer: state of the art and future perspectives.Defective DNA repair mechanisms in prostate cancer: impact of olaparibBeyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells.
P2860
Q26768661-548A4461-93A8-48F5-B836-438300AF7C80Q28271111-88FFEFDD-319D-4555-BBC2-E9420CFA6AA5Q33886191-36A69B9E-CDC7-4A18-865A-C56DDDF26952Q33891251-5C981B62-8693-47BD-9F2F-50BFFF23E6C8Q34501206-CB85E817-DF79-46D2-9DF7-4AAD07F19616Q34708560-6F18E053-9D38-49E2-A1A7-A771E50E46D5Q34770525-6AD49C32-8DE4-4194-BA65-14E157FDE9F0Q36841450-97864D7C-8B1D-4A3B-B110-5CEB11452345Q38101861-6BF345C1-A5F8-432C-95E1-4F4F2F3E2561Q38553247-D2EC93A4-8418-4018-8DCC-1394D767A9BEQ38616195-62CA443F-C27C-4E26-A00C-BB5257168E5FQ38692683-7670D7F8-B7C2-4D96-96DE-8A6A2FE603D3Q39171997-035B2785-597B-44C8-967B-B9B63D4DDE18Q39274912-0FB83B1A-A69A-4868-BC6F-F03D635926B0Q40661166-540FB0D5-0AD0-4B6F-84D9-EC12815214F3Q43300329-A6D7BE55-A27E-4A36-B589-6AEEF5BFFA84Q49385666-564D030A-6CC8-4E01-A870-702DA6166876
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Olaparib, PARP1 inhibitor in ovarian cancer.
@en
type
label
Olaparib, PARP1 inhibitor in ovarian cancer.
@en
prefLabel
Olaparib, PARP1 inhibitor in ovarian cancer.
@en
P2093
P2860
P50
P1476
Olaparib, PARP1 inhibitor in ovarian cancer
@en
P2093
Ludovica Imperiale
Pierluigi Benedetti Panici
Sandro Pignata
P2860
P304
P356
10.1517/13543784.2012.707189
P407
P577
2012-07-13T00:00:00Z